• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    REX American Resources Reports Upbeat Earnings, Joins Avalo Therapeutics, RH And Other Big Stocks Moving Higher On Thursday

    3/28/24 11:00:16 AM ET
    $ALT
    $ARHS
    $AVTX
    $DOOO
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Other Specialty Stores
    Consumer Discretionary
    Get the next $ALT alert in real time by email

    U.S. stocks were slightly higher, with the S&P 500 gaining around 0.1% on Thursday.

    Shares of REX American Resources Corporation (NYSE:REX) rose sharply during Thursday’s session following upbeat quarterly earnings.

    REX American Resources posted quarterly GAAP earnings of $1.16 per share, versus market estimates of 68 cents per share, according to data from Benzinga Pro.

    REX American Resources shares jumped 23.2% to $54.15 on Thursday.

    Here are some other big stocks recording gains in today’s session.

    • Avalo Therapeutics, Inc. (NASDAQ:AVTX) shares gained 430% to $25.35 after the company announced it acquired a Phase 2-ready anti-IL-1β mAb, which it refers to as AVTX-009, through the acquisition of privately held AlmataBio. The company also announced a private placement financing of up to $185 million.
    • Hut 8 Corp. (NASDAQ:HUT) surged 20.4% to $11.87. Hut 8 Corp reported revenue of C$60.6 million for the six months ended Dec. 31, 2023.
    • RH (NYSE:RH) gained 16.2% to $344.99 following the release of quarterly results. RH posted weaker-than-expected results for its fourth quarter, but issued upbeat forecast.
    • Sutro Biopharma, Inc. (NASDAQ:STRO) climbed 14.4% to $5.64. Oppenheimer analyst Jay Olson maintained Sutro Biopharma with an Outperform and maintained a $10 price target.
    • Nikola Corporation (NASDAQ:NKLA) rose 12.7% to $1.0250.
    • OPKO Health, Inc. (NASDAQ:OPK) rose 12.1% to $1.1996. Labcorp announced acquisition of select assets of BioReference Health's Diagnostics Business.
    • Altimmune, Inc. (NASDAQ:ALT) gained 11.4% to $9.90. Altimmune recently released lean mass preservation data for pemvidutide and worse-than-expected fourth-quarter FY23 earnings.
    • Marathon Digital Holdings, Inc. (NASDAQ:MARA) climbed 10.4% to $24.37.
    • Guardant Health, Inc. (NASDAQ:GH) gained 8.4% to $19.48.
    • Opendoor Technologies Inc. (NASDAQ:OPEN) surged 8% to $3.1850.
    • Arhaus, Inc. (NASDAQ:ARHS) gained 7.7% to $15.94.
    • Riot Platforms, Inc. (NASDAQ:RIOT) rose 6.8% to $13.07.
    • BRP Inc. (NASDAQ:DOOO) gained 6.4% to $67.74 after the company reported fourth-quarter results.
    • Encompass Health Corporation (NYSE:EHC) gained 5.8% to $82.06. Barclays analyst Andrew Mok maintained Encompass Health with an Overweight and raised the price target from $95 to $101.
    • The Estée Lauder Companies Inc. (NYSE:EL) rose 5.4% to $152.85 after B of A Securities upgraded the stock from Neutral to Buy and raised its price target from $160 to $170.
    • Exact Sciences Corporation (NASDAQ:EXAS) gained 4.7% to $70.01.

     

    Now Read This: Bitcoin Trades Above $70,000 Following GDP, Jobless Claims Data; GateToken Emerges As Top Gainer

    Get the next $ALT alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ALT
    $ARHS
    $AVTX
    $DOOO

    CompanyDatePrice TargetRatingAnalyst
    RH
    $RH
    3/25/2026$185.00 → $165.00Market Perform
    Telsey Advisory Group
    Sutro Biopharma Inc.
    $STRO
    3/24/2026$27.00Equal Weight → Overweight
    Wells Fargo
    Sutro Biopharma Inc.
    $STRO
    3/24/2026$28.00Neutral → Buy
    H.C. Wainwright
    Hut 8 Corp.
    $HUT
    3/23/2026$136.00Buy
    Arete
    Altimmune Inc.
    $ALT
    3/18/2026$12.00Buy
    Truist
    MARA Holdings Inc.
    $MARA
    2/27/2026Buy → Neutral
    H.C. Wainwright
    Arhaus Inc.
    $ARHS
    2/27/2026$12.00 → $11.00Market Perform
    Telsey Advisory Group
    Arhaus Inc.
    $ARHS
    2/26/2026$12.00 → $13.00Market Perform
    Telsey Advisory Group
    More analyst ratings

    $ALT
    $ARHS
    $AVTX
    $DOOO
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Telsey Advisory Group reiterated coverage on RH with a new price target

    Telsey Advisory Group reiterated coverage of RH with a rating of Market Perform and set a new price target of $165.00 from $185.00 previously

    3/25/26 8:14:41 AM ET
    $RH
    Other Specialty Stores
    Consumer Discretionary

    Sutro Biopharma upgraded by Wells Fargo with a new price target

    Wells Fargo upgraded Sutro Biopharma from Equal Weight to Overweight and set a new price target of $27.00

    3/24/26 8:28:11 AM ET
    $STRO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Sutro Biopharma upgraded by H.C. Wainwright with a new price target

    H.C. Wainwright upgraded Sutro Biopharma from Neutral to Buy and set a new price target of $28.00

    3/24/26 8:28:11 AM ET
    $STRO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ALT
    $ARHS
    $AVTX
    $DOOO
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    July 30, 2024 - FDA Roundup: July 30, 2024

    For Immediate Release: July 30, 2024 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  Today, the FDA is announcing the fiscal year (FY) 2025 user fee rates for importers approved to participate in the Voluntary Qualified Importer Program (VQIP) and accreditation and certification bodies interested in participating in the Accredited Third-Party C

    7/30/24 3:38:18 PM ET
    $GH
    Medical Specialities
    Health Care

    May 28, 2021 - FDA Approves First Targeted Therapy for Lung Cancer Mutation Previously Considered Resistant to Drug Therapy

    For Immediate Release: May 28, 2021 Today, the U.S. Food and Drug Administration approved Lumakras (sotorasib) as the first treatment for adult patients with non-small cell lung cancer whose tumors have a specific type of genetic mutation called KRAS G12C and who have received at least one prior systemic therapy. This is the first approved targeted therapy for tumors with any KRAS mutation, which accounts for ap

    5/28/21 1:05:48 PM ET
    $AMGN
    $GH
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Medical Specialities

    May 21, 2021 - FDA Approves First Targeted Therapy for Subset of Non-Small Cell Lung Cancer

    For Immediate Release: May 21, 2021 Today, the U.S. Food and Drug Administration approved Rybrevant (amivantamab-vmjw) as the first treatment for adult patients with non-small cell lung cancer whose tumors have specific types of genetic mutations: epidermal growth factor receptor (EGFR) exon 20 insertion mutations. The FDA also approved the Guardant360 CDx (Guardant Health Inc.) as a companion diagnostic for Ry

    5/21/21 12:50:51 PM ET
    $JNJ
    $GH
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Medical Specialities

    $ALT
    $ARHS
    $AVTX
    $DOOO
    SEC Filings

    View All

    $ALT
    $ARHS
    $AVTX
    $DOOO
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    $ALT
    $ARHS
    $AVTX
    $DOOO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    $ALT
    $ARHS
    $AVTX
    $DOOO
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form DEF 14A filed by Arhaus Inc.

    DEF 14A - Arhaus, Inc. (0001875444) (Filer)

    4/2/26 7:00:28 AM ET
    $ARHS
    Other Specialty Stores
    Consumer Discretionary

    SEC Form 15-12G filed by Exact Sciences Corporation

    15-12G - EXACT SCIENCES CORP (0001124140) (Filer)

    4/2/26 6:06:01 AM ET
    $EXAS
    Medical Specialities
    Health Care

    SEC Form EFFECT filed by Sutro Biopharma Inc.

    EFFECT - SUTRO BIOPHARMA, INC. (0001382101) (Filer)

    4/2/26 12:15:26 AM ET
    $STRO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Arhaus Expands in Northern Virginia with New Ashburn Showroom

    The artisan-crafted furnishings brand deepens its roots in Northern Virginia with a new showroom opening at One Loudoun BOSTON HEIGHTS, Ohio, April 03, 2026 (GLOBE NEWSWIRE) -- Arhaus, Inc. ("Arhaus" or the "Company") (NASDAQ:ARHS), a premium home furnishings brand known for responsibly sourced, artisan-crafted products and heirloom-quality design, today announced the opening of its new approximately 19,300-square-foot showroom in Ashburn, Virginia. Located within the One Loudoun, the new showroom marks Arhaus' fifth location in Virginia and reflects the brand's continued growth across the state. Inside the new showroom, clients can experience Arhaus' globally curated collections in an

    4/3/26 4:01:00 PM ET
    $ARHS
    Other Specialty Stores
    Consumer Discretionary

    Riot Announces First Quarter 2026 Production and Operations Updates

    CASTLE ROCK, Colo., April 02, 2026 (GLOBE NEWSWIRE) -- Riot Platforms, Inc. (NASDAQ:RIOT) ("Riot" or "the Company"), a Bitcoin-driven industry leader in the development of large-scale data centers and bitcoin mining applications, announces unaudited production and operations updates for the first quarter of 2026.   Bitcoin Production and Operations Updates for Q1 2026     Comparison (%)Metric Q1 2026 1Q1 2025 1Quarter/QuarterBitcoin Produced 1,4731,530-4%Average Bitcoin Produced per Day 16.417.0-4%Bitcoin Held 2 15,680 319,223-18%Bitcoin Sold 3,778-N/ABitcoin Sales - Net Proceeds $289.5 million-N/AAverage Net Price per Bitcoin Sold $76,626N/AN/ADeployed Hash Rate - Total 2 42.5 E+H/s33.7 E

    4/2/26 4:15:00 PM ET
    $RIOT
    Finance: Consumer Services
    Finance

    The Estée Lauder Companies Fully Establishes Its "One ELC" Operating Model and Reaches Milestone in Its Profit Recovery and Growth Plan

    WPP Appointed First-Ever Global Media Partner, Unifying Media Execution Worldwide "One ELC" Operating Model Is Transforming How the Company Operates at Scale The Estée Lauder Companies Inc. (NYSE:EL) today announced WPP as its first-ever global media partner, marking a significant advancement of its One ELC operating model, a scalable system designed to operate faster, execute with greater discipline, and drive growth. In fully establishing One ELC, the Company also reached a significant milestone in its Profit Recovery and Growth Plan's (PRGP) Restructuring Program — a key action plan priority of Beauty Reimagined. Stéphane de La Faverie, President and Chief Executive Officer, The Es

    4/1/26 5:00:00 PM ET
    $EL
    Package Goods/Cosmetics
    Consumer Discretionary

    SEC Form 4 filed by Khan Salman Hassan

    4 - MARA Holdings, Inc. (0001507605) (Issuer)

    4/3/26 7:00:06 PM ET
    $MARA
    EDP Services
    Technology

    SEC Form 4 filed by Thiel Frederick G

    4 - MARA Holdings, Inc. (0001507605) (Issuer)

    4/3/26 7:00:05 PM ET
    $MARA
    EDP Services
    Technology

    SEC Form 4 filed by Nowaid Zabi

    4 - MARA Holdings, Inc. (0001507605) (Issuer)

    4/3/26 7:00:03 PM ET
    $MARA
    EDP Services
    Technology

    Chief Financial Officer Weaver Gregory L bought $17,700 worth of shares (5,000 units at $3.54), increasing direct ownership by 22% to 28,078 units (SEC Form 4)

    4 - Altimmune, Inc. (0001326190) (Issuer)

    3/9/26 7:05:04 AM ET
    $ALT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    President and CEO Durso Jerome Benedict bought $70,790 worth of shares (20,000 units at $3.54), increasing direct ownership by 160% to 32,500 units (SEC Form 4)

    4 - Altimmune, Inc. (0001326190) (Issuer)

    3/9/26 7:00:05 AM ET
    $ALT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Pisano Wayne bought $20,410 worth of shares (5,000 units at $4.08), increasing direct ownership by 59% to 13,498 units (SEC Form 4)

    4 - Altimmune, Inc. (0001326190) (Issuer)

    1/9/26 4:10:05 PM ET
    $ALT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ALT
    $ARHS
    $AVTX
    $DOOO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by Estee Lauder Companies Inc.

    SC 13D/A - ESTEE LAUDER COMPANIES INC (0001001250) (Subject)

    12/10/24 6:06:03 PM ET
    $EL
    Package Goods/Cosmetics
    Consumer Discretionary

    Amendment: SEC Form SC 13D/A filed by Estee Lauder Companies Inc.

    SC 13D/A - ESTEE LAUDER COMPANIES INC (0001001250) (Subject)

    12/9/24 5:30:41 PM ET
    $EL
    Package Goods/Cosmetics
    Consumer Discretionary

    Amendment: SEC Form SC 13D/A filed by Estee Lauder Companies Inc.

    SC 13D/A - ESTEE LAUDER COMPANIES INC (0001001250) (Subject)

    12/9/24 5:30:28 PM ET
    $EL
    Package Goods/Cosmetics
    Consumer Discretionary

    $ALT
    $ARHS
    $AVTX
    $DOOO
    Leadership Updates

    Live Leadership Updates

    View All

    The Estée Lauder Companies Fully Establishes Its "One ELC" Operating Model and Reaches Milestone in Its Profit Recovery and Growth Plan

    WPP Appointed First-Ever Global Media Partner, Unifying Media Execution Worldwide "One ELC" Operating Model Is Transforming How the Company Operates at Scale The Estée Lauder Companies Inc. (NYSE:EL) today announced WPP as its first-ever global media partner, marking a significant advancement of its One ELC operating model, a scalable system designed to operate faster, execute with greater discipline, and drive growth. In fully establishing One ELC, the Company also reached a significant milestone in its Profit Recovery and Growth Plan's (PRGP) Restructuring Program — a key action plan priority of Beauty Reimagined. Stéphane de La Faverie, President and Chief Executive Officer, The Es

    4/1/26 5:00:00 PM ET
    $EL
    Package Goods/Cosmetics
    Consumer Discretionary

    RH Announces the Appointment of Veronica Schnitzius as President, Chief Manufacturing & Sourcing Officer

    RH (NYSE:RH) announced today that Veronica Schnitzius is joining the Company as President, Chief Manufacturing & Sourcing Officer. Veronica will lead RH's efforts to build a global manufacturing platform that combines owned and operated, joint-ventured, and outsourced manufacturing for the Company's core furniture business, which represents 80% of RH brand revenues. The strategy will emulate the vertically integrated model of many of the world's largest and most profitable luxury brands that have a high level of control over the manufacturing, quality and capacity of their core business. Mrs. Schnitzius joins RH after a distinguished 24-year career at American Leather, a leading U.S. br

    3/27/26 8:00:00 AM ET
    $RH
    Other Specialty Stores
    Consumer Discretionary

    RH Announces the Appointment of David Stanchak as Chief Real Estate and Transformation Officer

    RH (NYSE:RH) today announced that David Stanchak has returned to the Company as Chief Real Estate and Transformation Officer. Mr. Stanchak has resumed his role leading the Company's Global Real Estate Expansion and North American Gallery Transformation, a position he held from May 2015 through May 2021. Mr. Stanchak will also be leading efforts to monetize the Company's significant portfolio of real estate assets in the United States and Europe. RH Chairman and Chief Executive Officer, Gary Friedman commented, "We are thrilled Dave is rejoining Team RH. His leadership expanding our Gallery platform globally, transforming our legacy stores into Design Galleries with integrated Restaurant

    3/26/26 5:49:00 PM ET
    $RH
    Other Specialty Stores
    Consumer Discretionary

    $ALT
    $ARHS
    $AVTX
    $DOOO
    Financials

    Live finance-specific insights

    View All

    RH to Report Fourth Quarter and Fiscal Year 2025 Financial Results on March 31, 2026

    RH (NYSE:RH) today announced that it will report financial results for the fourth quarter and fiscal year 2025 ended January 31, 2026, on Tuesday, March 31, 2026, after market close. RH's fourth quarter and fiscal year 2025 financial results will include a video presentation from Gary Friedman, RH Chairman and Chief Executive Officer, highlighting the Company's continued evolution and recent performance. The video presentation will be posted to the Company's investor relations website at ir.rh.com. RH leadership will host a live webcast of the video presentation followed by Q&A at 2:00 pm Pacific Time (5:00 pm Eastern Time) on March 31, 2026, at ir.rh.com. A replay will also be available

    3/26/26 4:05:00 PM ET
    $RH
    Other Specialty Stores
    Consumer Discretionary

    REX American Resources Reports Record High Full Fiscal Year 2025 Net Income Per Share Attributable to REX Common Shareholders of $2.50

    Generated $1.32 of net income per share in fourth quarter and $2.50 of net income per share in Full Fiscal Year ‘25 Reported gross profit of $28.9 million for fourth quarter and $93.7 million for Full Fiscal Year ‘25 Reported net sales and revenue of $158.0 million for fourth quarter and $650.5 million for Full Fiscal Year '25 Reported consolidated ethanol sales volumes of 70.1 million gallons for fourth quarter and 290.0 million gallons for Full Fiscal Year '25 REX American Resources Corporation ("REX" or the "Company") (NYSE:REX), a leading ethanol production company, today announced financial and operational results for the Company's full year and fiscal fourth quarter 2025.

    3/26/26 7:30:00 AM ET
    $REX
    Major Chemicals
    Industrials

    REX American Resources to Report Q4 and Full Fiscal Year 2025 Results and Host a Conference Call and Webcast on March 26, 2026

    REX American Resources Corporation ("REX" or the "Company") (NYSE:REX), a leading ethanol production company, announced today that it will report its fiscal fourth quarter and full fiscal year 2025 operational and financial results on Thursday, March 26, 2026 pre-market and will host a conference call and webcast at 11:00 a.m. ET that morning to review the results. To access the conference call, interested parties may dial (877) 269-7751 (US) or (201) 389-0908 (international). Participants can also listen to a live webcast of the call by going to the Investors section on the REX website at www.rexamerican.com. A replay will be available shortly after the live conference call and can be ac

    3/12/26 7:30:00 AM ET
    $REX
    Major Chemicals
    Industrials